What's new — Type 2 diabetes¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 6 |
| last 2 months | 16 |
| last 3 months | 18 |
| last 6 months | 22 |
| last year | 32 |
| older than a year | 233 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-17 | Department of Error — Lancet ([PMID 42880309](https://pubmed.ncbi.nlm.nih.gov/42880309/){target="_blank" rel="noopener"}) | incretin-therapies |
| 2026-10-02 | Correction: Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) — Diabetologia ([PMID 42955083](https://pubmed.ncbi.nlm.nih.gov/42955083/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | A Malaysian Expert Consensus on The Identification, Evaluation, and Pharmacological Management of Diabetic Sensorimotor Polyneuropathy — Diabetes Ther ([PMID 42928304](https://pubmed.ncbi.nlm.nih.gov/42928304/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial — PLoS One ([PMID 42912779](https://pubmed.ncbi.nlm.nih.gov/42912779/){target="_blank" rel="noopener"}) | glycemic-management-and-legacy-trials |
| 2026-10-02 | Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study — Diabetes Care ([PMID 42900776](https://pubmed.ncbi.nlm.nih.gov/42900776/){target="_blank" rel="noopener"}) | metabolic-surgery |
| 2026-10-02 | Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) — Diabetes Care ([PMID 42825450](https://pubmed.ncbi.nlm.nih.gov/42825450/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-01 | A Conversation Tool to Enhance Care for People With Type 2 Diabetes: The QBSafe Cluster Randomized Clinical Trial — JAMA Netw Open ([PMID 42895748](https://pubmed.ncbi.nlm.nih.gov/42895748/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-01 | Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes — N Engl J Med ([PMID 42878622](https://pubmed.ncbi.nlm.nih.gov/42878622/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glycemic-management-and-legacy-trials |
| 2026-10-01 | Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes — N Engl J Med ([PMID 42820639](https://pubmed.ncbi.nlm.nih.gov/42820639/){target="_blank" rel="noopener"}) | clinical-trials-landscape, incretin-therapies |
| 2026-09-03 | Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial — Lancet ([PMID 42815506](https://pubmed.ncbi.nlm.nih.gov/42815506/){target="_blank" rel="noopener"}) | clinical-trials-landscape, incretin-therapies |
| 2026-09-02 | Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial — Lancet ([PMID 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/){target="_blank" rel="noopener"}) | clinical-trials-landscape, incretin-therapies |
| 2026-09-02 | EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy — J Hepatol ([PMID 42805503](https://pubmed.ncbi.nlm.nih.gov/42805503/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-01 | Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation — BMJ ([PMID 42778221](https://pubmed.ncbi.nlm.nih.gov/42778221/){target="_blank" rel="noopener"}) | sglt2-inhibitors-and-kidney-heart |
| 2026-09-01 | 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetes — Diabetologia ([PMID 42744915](https://pubmed.ncbi.nlm.nih.gov/42744915/){target="_blank" rel="noopener"}) | guidelines, patient-experience-and-advocacy |
| 2026-09-01 | Interventions to reduce diabetes-related distress among adults with type 1 or type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials — Diabetologia ([PMID 42726276](https://pubmed.ncbi.nlm.nih.gov/42726276/){target="_blank" rel="noopener"}) | guidelines, patient-experience-and-advocacy |
| 2026-09-01 | Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study — Lancet Diabetes Endocrinol ([PMID 42679839](https://pubmed.ncbi.nlm.nih.gov/42679839/){target="_blank" rel="noopener"}) | sglt2-inhibitors-and-kidney-heart |
| 2026-08-07 | Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis — Lancet Diabetes Endocrinol ([PMID 42567173](https://pubmed.ncbi.nlm.nih.gov/42567173/){target="_blank" rel="noopener"}) | incretin-therapies |
| 2026-08-02 | Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data — Nephrol Dial Transplant ([PMID 42658186](https://pubmed.ncbi.nlm.nih.gov/42658186/){target="_blank" rel="noopener"}) | clinical-trials-landscape, incretin-therapies, sglt2-inhibitors-and-kidney-heart |
| 2026-08-01 | Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial — Lancet Diabetes Endocrinol ([PMID 42594928](https://pubmed.ncbi.nlm.nih.gov/42594928/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-08-01 | Promoting Stigma-Free Language in Type 2 Diabetes Care Among Primary Care Clinicians: Randomized Controlled Pilot Trial — JMIR Diabetes ([PMID 42579884](https://pubmed.ncbi.nlm.nih.gov/42579884/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-07-02 | The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis — Surg Obes Relat Dis ([PMID 42660781](https://pubmed.ncbi.nlm.nih.gov/42660781/){target="_blank" rel="noopener"}) | metabolic-surgery, remission-and-weight-management |
| 2026-06-02 | A systematic review and meta-analysis of the association between low socioeconomic status and all-cause mortality in patients with diabetes — Front Public Health ([PMID 42433401](https://pubmed.ncbi.nlm.nih.gov/42433401/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-05-01 | A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial — Lancet Diabetes Endocrinol ([PMID 42114520](https://pubmed.ncbi.nlm.nih.gov/42114520/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-03-02 | Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials — Pancreatology ([PMID 41927408](https://pubmed.ncbi.nlm.nih.gov/41927408/){target="_blank" rel="noopener"}) | incretin-therapies, red-flags-and-safety-concerns |
| 2026-03-01 | Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes? — Diabetes Obes Metab ([PMID 41852334](https://pubmed.ncbi.nlm.nih.gov/41852334/){target="_blank" rel="noopener"}) | remission-and-weight-management |
| 2026-01-01 | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358900](https://pubmed.ncbi.nlm.nih.gov/41358900/){target="_blank" rel="noopener"}) | complications, glycemic-management-and-legacy-trials, guidelines, overview, patient-experience-and-advocacy, red-flags-and-safety-concerns, youth-onset-t2d |
| 2026-01-01 | 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358899](https://pubmed.ncbi.nlm.nih.gov/41358899/){target="_blank" rel="noopener"}) | complications, guidelines, overview, red-flags-and-safety-concerns, sglt2-inhibitors-and-kidney-heart |
| 2026-01-01 | Summary of Revisions: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358896](https://pubmed.ncbi.nlm.nih.gov/41358896/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-01 | 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358893](https://pubmed.ncbi.nlm.nih.gov/41358893/){target="_blank" rel="noopener"}) | biomarkers, guidelines, overview, prevention, red-flags-and-safety-concerns |
| 2026-01-01 | 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358886](https://pubmed.ncbi.nlm.nih.gov/41358886/){target="_blank" rel="noopener"}) | complications, guidelines, overview, red-flags-and-safety-concerns, youth-onset-t2d |
| 2025-12-18 | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes — N Engl J Med ([PMID 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/){target="_blank" rel="noopener"}) | clinical-trials-landscape, incretin-therapies |
| 2025-11-01 | Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO — Clin J Am Soc Nephrol ([PMID 41314692](https://pubmed.ncbi.nlm.nih.gov/41314692/){target="_blank" rel="noopener"}) | youth-onset-t2d |
Trials — what has moved¶
19 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 1 |
| trial records updated in the last 2 months | 2 |
| trial records updated in the last 3 months | 6 |
| trial records updated in the last 6 months | 10 |
| trial records updated in the last year | 12 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for | NA | 154 | Illness Intrusiveness Measured by the Illness Intrusiveness Ratings Sc | 0 | 0 | 3 |
| 2026-07-08 | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major | PHASE3 | 13299 | Number of Participants From Randomization to First Occurrence of Death | 4238 | 9015 | 1238 |
| 2025-09-26 | A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescen | PHASE3 | 99 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzep | 5 | 72 | 0 |
| 2025-09-22 | A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | PHASE3 | 9651 | Number of Participants From Randomization to First Occurrence of a Maj | 4739 | 3360 | 1107 |
| 2025-03-20 | A Research Study to See How Semaglutide Works Compared to Placebo in P | PHASE3 | 3533 | Number of Participants From Time of Randomization to First Occurrence | 1827 | 1029 | 506 |
| 2024-08-30 | Semaglutide Effects on Heart Disease and Stroke in Patients With Overw | PHASE3 | 17604 | Participants From Time of Randomization to First Occurrence of a Compo | 6145 | 6384 | 831 |
| 2019-11-20 | Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular | PHASE3 | 4401 | Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End | 1543 | 2767 | 357 |
| 2018-03-15 | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Sem | PHASE3 | 3297 | Time From Randomisation to First Occurrence of a MACE, Defined as Card | 1192 | 2231 | 0 |
| 2017-03-01 | Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascula | PHASE3 | 9341 | Time From Randomisation to First Occurrence of Cardiovascular Death, N | 4674 | 894 | 0 |
| 2016-05-16 | BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 | PHASE3 | 7064 | Time to the First Occurrence of Any of the Following Adjudicated Compo | 2777 | 4797 | 0 |
3 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| incretin-therapies | 2026-10-17 | 8 | 44 |
| glycemic-management-and-legacy-trials | 2026-10-02 | 3 | 37 |
| guidelines | 2026-10-02 | 11 | 38 |
| metabolic-surgery | 2026-10-02 | 2 | 35 |
| clinical-trials-landscape | 2026-10-01 | 9 | 41 |
| patient-experience-and-advocacy | 2026-09-01 | 4 | 38 |
| sglt2-inhibitors-and-kidney-heart | 2026-09-01 | 4 | 39 |
| remission-and-weight-management | 2026-07-02 | 2 | 38 |
| epidemiology-and-burden | 2026-06-02 | 1 | 37 |
| red-flags-and-safety-concerns | 2026-03-02 | 5 | 37 |
| biomarkers | 2026-01-01 | 1 | 34 |
| complications | 2026-01-01 | 3 | 35 |
| overview | 2026-01-01 | 4 | 50 |
| prevention | 2026-01-01 | 1 | 37 |
| youth-onset-t2d | 2026-01-01 | 3 | 36 |
| pathophysiology-and-subtypes | 2024-07-01 | 0 | 36 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.